Share this page!

Enter URL or ID to Unroll

You can paste full URL like: https://x.com/threadreaderapp/status/1644127596119195649
or just the ID like: 1644127596119195649

How to get URL link on X (Twitter) App

  1. On the Twitter thread, click on or icon on the bottom
  2. Click again on or Share Via icon
  3. Click on Copy Link to Tweet
  4. Paste it above and click "Unroll Thread"!
  5. More info at Twitter Help
The Sato Lab (Kei Sato) Profile picture
@SystemsVirology
Feb 11 • 7 tweets • 3 min read • Read on X
BREAKING🔔 The 50th🎉 paper from G2P-Japan🇯🇵 is out at Lancet Infectious Diseases
@TheLancetInfDis. We elucidated the virological characteristics of SARS-CoV-2 LP.8.1. Please repost🔥 1/
thelancet.com/journals/lanin…
In spike, LP.8.1 has 9 mutations (S31del, F186L, R190S, R346T, V445R, F456L, Q493E, K1086R, and V1104L) compared with JN.1; and 8 amino acid residues (T22N, S31del, F59S, F186L, R190S, R346T, H445R, and K1086R) differ between the spike proteins of LP.8.1 and XEC. 2/ Image
Transmissibility/fitness (Re):
Epidemic dynamics modeling led by Jumpei @jampei2 and Kaho showed that the Re of LP.8.1 is ~1.1-fold higher than that of XEC in 🇺🇸. However, the Re of LP.8.1 and XEC were almost comparable in 🇯🇵. Difference between countries🤔?? 3/ Image
Pseudovirus infectivity:
LP.8.1 < XEC = JN.1. Difference between our data (figure) and that from Yunlong @yunlong_cao (url link below) might be due to difference in experimental setup (pseudovirus vs RBD)🤔?? 4/
biorxiv.org/content/10.110…Image
Immune resistance:
In all cases tested, the 50% neutralization titers (NT50s) of XEC and LP.8.1 were comparable. So... why is the Re of LP.8.1 higher than that of XEC...🤔? 5/ Image
The advantage of LP.8.1 over XEC may depend on the immune background and/or the history of SARS-CoV-2 infection/vaccination of the population in each country? Anyways both live-virus and real-world data from more countries would be needed to better understand of LP.8.1... 6/
Over the next few months, pharmaceutical companies will be considering the vaccine variant for fall/winter 2025. It would be particularly important to take into account our data suggesting that LP.8.1 may NOT be dominant globally when considering the vaccine candidate. 7/7

• • •

Missing some Tweet in this thread? You can try to force a refresh
　

Keep Current with The Sato Lab (Kei Sato)

The Sato Lab (Kei Sato) Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @SystemsVirology

The Sato Lab (Kei Sato) Profile picture
Nov 21, 2024
#拡散希望 速報🔔 G2P-Japan🇯🇵の新しいプレプリント「JN.1対応mRNAワクチンが誘導する中和抗体の効果の評価」を、bioRxiv @biorxivpreprint に発表しました。1/
biorxiv.org/content/10.110…
本研究では、#ファイザー 🇺🇸🇩🇪のワクチンと、#第一三共 🇯🇵の国産ワクチンを接種した方の、ワクチン接種前後の血清を用いた検討実験を行いました。
まず朗報として、２つのワクチンで誘導される中和抗体の活性に大差はなく、どちらの血清も、JN.1のみならずKP.3.1.1やXECの感染を強く抑制しました。2/ Image
しかし、科学的観点からは、注目すべき点がふたつ。

その１。われわれは最近、JN.1やKP.3.3の「自然感染」では、強い中和抗体活性が誘導されないことを示しました。しかし上述の通り、JN.1ワクチンでは、強い中和活性（NT50; 50%中和抗体価）が誘導されています。この違いはいったい🤔？ 3/ Image
Read 9 tweets
The Sato Lab (Kei Sato) Profile picture
Nov 21, 2024
BREAKING🔔 A new study from G2P-Japan🇯🇵, led by Keiya @Keiya717, is out at @biorxivpreprint. We assessed the humoral immunity induced by JN.1 mRNA vaccines against a broad range of SARS-CoV-2 variants including JN.1, KP.3.1.1 & XEC. Please repost🔥 1/
biorxiv.org/content/10.110…
In this study, we used 2 mRNA vaccines, one is from Pfizer/BioNTech🇺🇸🇩🇪, while another is from Daiichi-Sankyo🇯🇵. The good news is that there are no significant differences between them and both broadly neutralized a variety of SARS-CoV-2 including JN.1, KP.3.1.1 and XEC. 2/ Image
But there are two scientific interests.

First, compared to our recent study using JN.1 and KP.3.3 breakthrough (i.e. natural) infection sera, antiviral humoral immunity against KP.3 and XEC was weakly induced. However, JN.1 mNRA vaccine can. Why🤔?? 3/ Image
Read 8 tweets
The Sato Lab (Kei Sato) Profile picture
Oct 17, 2024
BREAKING🔔 A new study from G2P-Japan🇯🇵, led by Yu in my lab, is out at bioRxiv @biorxivpreprint. We elucidated the virological characteristics of SARS-CoV-2 #XEC. Please repost🔥 1/
biorxiv.org/content/10.110…
Compared with KP.3, #XEC harbors two spike substitutions, S:T22N and S:F59S. Recombination analysis by Shusuke @KawakuboShusuke showed that XEC is a recombinant lineage of KS.1.1 (JN.13.1.1.1) and KP.3.3 (JN.1.11.1.3.3) with a breakpoint at genomic position 21,738–22,599. 2/ Image
Image
Transmissibility/fitness (Re):
Molecular phylogenetic-epidemic dynamics modeling led by Jumpei @jampei2 and Kaho showed that the Re of #XEC is greater than that of KP.3.1.1, the most predominant variant in the world. 3/ Image
Read 7 tweets
The Sato Lab (Kei Sato) Profile picture
Jul 17, 2024
#拡散希望 速報🔔 G2P-Japan🇯🇵の新しい研究成果「新型コロナウイルス変異株KP.3.1.1のウイルス学的特性の解明」について、プレプリント公開に先立って速報します。本研究では、最近いくつかの国で増加傾向にある、JN.1の子孫株である新しい変異株KP.3.1.1の特性を検証しました。1/
春になり、JN.1の子孫株が出現し、それらが優勢になり始めています。現在本邦は第11波に入っていますが、それはこれらのJN.1の子孫株によって引き起こされています。現在の流行状況などについては、本日公開の最新コラムで解説しています↓ 2/
そのひとつ、KP.2 (JN.1.11.1.2)については、すでにG2P-Japan🇯🇵が論文として報告しています。3/
Read 10 tweets
The Sato Lab (Kei Sato) Profile picture
Jul 17, 2024
BREAKING🔔 Here I want to quickly report our new results from G2P-Japan🇯🇵 before the preprint publication. We have elucidated the virological characteristics of SARS-CoV-2 KP.3.1.1 - a progeny of JN.1. Please RT🔥 1/
Cf.1 A new one, KP.2 (JN.1.11.1.2), has been already elucidated. 2/
Cf.2 Another new ones, KP.3 (JN.1.11.1.3), LB.1 (JN.1.9.2.1) and KP.2.3 (JN.1.11.1.2.3), have also been already elucidated. 3/
Read 8 tweets
The Sato Lab (Kei Sato) Profile picture
Jun 6, 2024
#拡散希望 速報🔔 G2P-Japan🇯🇵の新しい研究成果「新型コロナウイルス変異株KP.3, LB.1, KP.2.3のウイルス学的特性の解明」について、プレプリント公開に先立って速報します。本研究では、最近いくつかの国で増加傾向にある、JN.1の子孫株である新しい3つの変異株の特性を検証しました。1/
春になり、JN.1の子孫株が出現し、それらが優勢になり始めています。そのひとつ、KP.2 (JN.1.11.1.2)の特性については、すでにG2P-Japan🇯🇵が論文として報告しています。2/
今回着目したのは、KP.2にやや遅れて出現した3つの株、KP.3 (JN.1.11.1.3)、LB.1 (JN.1.9.2.1)、KP.2.3 (JN.1.11.1.2.3)です。それぞれ、こんな変異を持っています。
（＊参考まで、JN.1=BA.2.86.1.1で、BA.2.86系統の子孫株）3/ Image
Read 8 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

Send Email!

:(